SOX2 and breast cancer: Taken together, our results highlight the importance of the AKT/SOX2 axis for BC clonogenicity and in vivo tumorigenicity, and indicate AKT inhibitors as molecules targeting SOX2-positive BC (stem) cells via SOX2 protein depletion.